Hanzl, Alexander http://orcid.org/0000-0002-6004-2312
Casement, Ryan http://orcid.org/0000-0002-5008-9491
Imrichova, Hana http://orcid.org/0000-0003-0385-1823
Hughes, Scott J.
Barone, Eleonora
Testa, Andrea
Bauer, Sophie
Wright, Jane
Brand, Matthias
Ciulli, Alessio http://orcid.org/0000-0002-8654-1670
Winter, Georg E. http://orcid.org/0000-0001-6606-1437
Article History
Received: 2 June 2022
Accepted: 20 September 2022
First Online: 3 November 2022
Competing interests
: S.B. is an employee at Proxygen, a company that is developing molecular glue degraders. M.B. is scientific founder, shareholder and employee at Proxygen. G.E.W. is scientific founder and shareholder at Proxygen and Solgate and the Winter laboratory receives research funding from Pfizer. A.C. is a scientific founder, shareholder and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. S.J.H. and A.T. are currently employees of Amphista Therapeutics. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. The other authors are not aware of any affiliations, memberships, funding or financial holdings that might be perceived as affecting the objectivity of this work.